Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data
Novo Nordisk stock gained on Tuesday alongside new weight-loss data from women who used CagriSema.
Novo Nordisk A S (NVO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 7,461 | $282,847 | +1% | 0.01% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,181,453 | $120,608,883 | 6.64% | |
| 2. | 593,191 | $27,209,442 | 2.23% | |
| 3. | 458,256 | $17,138,774 | 1.02% | |
| 4. | 435,485 | $16,509,236 | 1.09% | |
| 5. | 426,700 | $16,176,197 | 1.39% |
News See All
Eli Lilly Stock (LLY) Hits All-Time High Ahead of Earnings
The pharma giant reports financial results on Oct. 29.
Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
Novo Nordisk S/A (NYSE:NVO)'s investment story has changed dramatically. The stock has declined by over 25% since the start of 2026. The selloff has changed the stock's valuation.
Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
Novo Nordisk (NYSE:NVO) did something this year that usually pleases investors: it raised its full-year outlook.
Eli Lilly and Novo Face New Pressure from WHO’s Childhood Obesity Guidelines
The World Health Organization (WHO) issued its first-ever guidelines on childhood and adolescent obesity on Wednesday. The guidelines discourage we...
AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
AI startup BioinvestGPT predicted the failure of Novartis AG’s ($NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 re...
Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response
During the October 1 lightning round of Mad Money, a caller said they owned both Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY).
Novo Looks Beyond GLP-1s as Competition Intensifies
In the past, Novo Nordisk A/S (NYSE:NVO) has been a dominant player in diabetes and obesity treatments, with Ozempic and Wegovy driving a significant portion of the company’s recent growth.
Eli Lilly Stock (LLY) Moves Higher on Positive Trial Results for Zepbound Combo
The company has developed several medications for weight loss and diabetes.
Novo vs. Eli Lilly: Study Shows Ozempic Advantage over Mounjaro — Why This Matters for NVO Investors
Danish drug giant Novo ($NVO), in a Tuesday press statement, announced key findings from a real-world study that pitched its diabetes drug against ...
Hedge Fund Resource Center